Congress Passes Breast/Cervical Cancer Bill

Publication
Article
OncologyONCOLOGY Vol 14 No 12
Volume 14
Issue 12

Congress finally passed a bill (H.R. 4386/S. 662) that allows states to provide medical treatment for women with breast and cervical cancer. At their option (there is no requirement), states can treat women who have tested positive in a screening

Congress finally passed a bill (H.R. 4386/S. 662) that allows states to providemedical treatment for women with breast and cervical cancer. At their option(there is no requirement), states can treat women who have tested positive in ascreening program run by the Centers for Disease Control and Prevention (CDC).Frequently, these screening programs are located at community health clinics inpoor urban areas and on Native American reservations, clinics funded by theHealth Resources and Services Administration (HRSA). Nearly 2 million women havebeen screened since 1990. The budget in fiscal year 2000 for this NationalBreast and Cervical Cancer Early Detection Program was $167 million. In thepast, many of the women diagnosed with cancer had nowhere to turn for medicaltreatment because they were uninsured. The Breast and Cervical Cancer TreatmentAct opens up a treatment avenue for some of them. States will be able to providetreatment through Medicaid, and will get an enhanced federal matching grant forestablishing that treatment program.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Breast oncologist Jade E. Jones, MD, says she tries to send patients with BRCA-mutant HR-positive TNBC to clinical trials that use PARP inhibitors.
Following progression on a CDK4/6 inhibitor, ascertaining the endocrine sensitivity of HR-positive/HER2-negative disease may inform sequential treatment.
T-DXd improved progression-free survival over standard chemotherapy among patients with HR-positive/triple-negative breast cancer in DESTINY-Breast04.
According to Maurie Markman, MD, patient-reported outcomes pertain to more relevant questions surrounding the impact of therapy for patients.
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practices in the breast cancer field.
Related Content